Allergan Acquires Aneterios
Allergan has acquired Anterios, Inc., a clinical-stage biopharmaceutical company developing a delivery system and botulinum toxin-based prescription products. Under the terms of the agreement, Allergan acquired Anterios for an upfront payment of $90 million and potential development and commercialization milestone payments related to NDS, Anterios’ proprietary platform delivery technology that enables local, targeted delivery of neurotoxins through the skin without the need for injections.
In addition to NDS, Allergan has acquired global rights to ANT-1207, an investigational topical formulation botulinum toxin type A in development for the potential treatment of hyperhidrosis (excessive sweating), acne, and crow’s feet lines.
The NDS platform technology and ANT-1207 add to Allergan’s neurotoxin pipeline, with Botox Cosmetic (onabotulinumtoxinA), currently in development for treating forehead lines, masseter hypertrophy and platysma bands and Botox Therapeutic in development for osteoarthritis and depression.
Prior to the closing, Anterios spun out certain assets to a new company, Eirion Therapeutics, Inc., funded by Anterios shareholders. The new entity also retains certain non-exclusive rights to ANT-1207.